Clinical trial
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
NCT00207727 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00207727 |
|---|---|
| Title | A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis |
| Official title | A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis |
| Lead sponsor | Centocor, Inc., Industry |
| Collaborators | Centocor BV Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | CNTO 1275 |
| Enrollment | 249 |
| Start date | Jul 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Apr 23, 2012 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: